Target intelligence / Profile preview

Activating transcription factor 6 alpha (ATF6) (ATF6)

Target
ATF6
Molecular classification
Transcription factor, Other
01

Overview

Activating transcription factor 6 alpha (ATF6) is a type II transmembrane protein located in the endoplasmic reticulum (ER) that serves as a primary sensor for the unfolded protein response (UPR) (UniProt P18850). The luminal domain of ATF6 is essential for sensing ER stress; under normal conditions, it is bound by the chaperone BiP (GRP78), which prevents its transport to the Golgi (Haze et al., 1999). When misfolded proteins accumulate, BiP dissociates, allowing ATF6 to translocate to the Golgi where it is cleaved by Site-1 and Site-2 proteases (S1P/S2P) to release its active transcription factor fragment (Ye et al., 2000). This active fragment migrates to the nucleus to induce the expression of ER chaperones and ERAD components to restore proteostasis (Adachi et al., 2008). Mutations in the ATF6 luminal domain are a known cause of achromatopsia, a hereditary visual disorder (Kohl et al., 2015). Therapeutically, the luminal domain is targeted by small molecules like Ceapins, which selectively inhibit ATF6 signaling by inducing its clustering and preventing Golgi translocation (Gallagher et al., 2016). Conversely, selective activators like AA147 target the ATF6 pathway to enhance ER folding capacity, offering potential treatments for neurodegenerative and cardiovascular diseases (Plate et al., 2016).

Other names
ATF6AATF6-alphaCyclic AMP-dependent transcription factor ATF-6 alphaProcessed cyclic AMP-dependent transcription factor ATF-6 alpha
02

Mechanism of action

Small molecule modulation of ATF6 ER-to-Golgi translocation and subsequent proteolytic activation to regulate the unfolded protein response.

03

Biological functions

Signal transductionProtein foldingEndoplasmic reticulum-associated degradation (ERAD)HomeostasisOther
04

Disease associations

CancerNeurodegenerative diseaseCardiovascular diseaseOther
05

Safety considerations

Potential for ER stress-induced apoptosisSystemic disruption of the secretory pathwayOff-target effects on PERK and IRE1 pathways
06

Interacting drugs

Ceapin-A7

2 more in the full profile.

07

Biomarkers

ATF6 cleavage product (p50 fragment)GRP78 (BiP) expression levelsHERPUD1 mRNA levels

Beyond the preview

Go deeper on Activating transcription factor 6 alpha (ATF6) (ATF6).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Activating transcription factor 6 alpha (ATF6) (ATF6).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call